GSTP1 and pancreatic neoplasm: Indeed, tumor expression of GSTP1 does not predict the safety or efficacy of platinum-based chemotherapy regimen Folfirinox (leucovorin, fluorouracil, irinotecan, and oxaliplatin) in patients with pancreatic cancer [147].